News - Appointments

Immunocore Ltd has appointed Brian Di Donato as chief financial officer and head of strategy as its lead cancer compound enters pivotal clinical studies.

Nordic Nanovector ASA has restructured its senior management team and promoted Malene Brondberg to the position of chief financial officer from head of investor relations, reporting to Lars Nieba, the interim chief executive.

Ian Catchpole has been appointed chief scientific officer at France-based Horama SA, which is developing gene therapies to treat rare ophthalmic diseases.

Sonia Quaratino has been appointed chair of the scientific and clinical advisory board of STipe Therapeutics ApS, a 2018 spinout of Aarhus University in Denmark which is targeting the innate immune system for cancer treatments.

Danny Bar-Zohar, a surgeon and pharmaceutical industry executive, has joined Syncona Ltd as partner to help the investment group build its portfolio of life science companies.

Basilea Pharmaceutica Ltd has appointed Savitha Ram Moorthi as head of global quality management, effective 1 June, to oversee product quality at the Switzerland-based biopharmaceutical company.

Switzerland-based GeNeuro SA has hired the neurologist David Leppert to be chief medical officer and manage development of its programmes for neurodegenerative and autoimmune diseases.

Roland Wandeler, a former executive at Amgen Inc, has been appointed chief commercial officer at MorphoSys AG whose lead cancer product is under priority review at the US Food and Drug Administration.

Angus Lauder, a former executive at the UK’s leading cancer charity, has been named director of business development at Storm Therapeutics Ltd to help manage that company’s portfolio of epigenetic medicines.

Jonathan Tobin has been promoted to the position of managing director of Arix Bioscience Plc from investment director.